A multicentre randomized, double-blind, placebo-controlled, dose-finding, Phase 2 study (MARS-17) of GSK3858279 in adult participants with moderate to severe pain due to knee osteoarthritis.

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-502799-22-00

Acronym

209978

Enrollment

Registered

2023-07-13

Start date

2023-11-29

Completion date

2024-08-05

Last updated

2024-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Knee osteoarthritis pain

Brief summary

Change from baseline at Week 12 in weekly average of average daily pain intensity, assessed on the Numeric Rating Scale (NRS)

Interventions

DRUGSterile 0.9% (w/v) Sodium Chloride

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Change from baseline at Week 12 in weekly average of average daily pain intensity, assessed on the Numeric Rating Scale (NRS)	—

Countries

France, Germany, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026